Search

Displaying results 4971 - 4980 of 9333 in total
  1. Drug

    XL844

    go.drugbank.com/drugs/DB05149
    Investigational

    XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents. … XL844 is investigated for the use and treatment solid tumors. XL844 is a solid.

  2. Drug

    Amlitelimab

    go.drugbank.com/drugs/DB18835
    Investigational

    and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)). … Amlitelimab is under investigation in clinical trial NCT06181435 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years

  3. Drug

    SYN-101

    go.drugbank.com/drugs/DB05958
    Experimental

    SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells. … SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer.

  4. Drug

    CoVac-1

    go.drugbank.com/drugs/DB16429
    Investigational

    T-cell immunity[A226588]. … Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein[A226588].

  5. Drug

    MLN-977

    go.drugbank.com/drugs/DB05431
    Experimental

    MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.

  6. Drug

    Deracoxib

    go.drugbank.com/drugs/DB11395
    ExperimentalVet approved

    Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. … It is sold in tablets, which have added beefy flavour to increase palatability.

  7. Drug

    V591

    go.drugbank.com/drugs/DB16438
    Investigational

    Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I clinical trials (NCT04498247)[L30593]. … The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery[L30593].

  8. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    As a result, Sanofi stopped the development of the drug. … It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding.

  9. Drug

    Probiorinse

    go.drugbank.com/drugs/DB15870
    Experimental

    [L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.[A220193] … Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.

  10. Drug

    CK0802

    go.drugbank.com/drugs/DB15866
    Investigational

    [L16358] On the surface of these T-Reg cells, T-cell lung homing markers are expressed. … CK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching.

    Synonyms: Allogeneic Umbilical Cord Blood Derived Regulatory T-Cells